Truist Financial Has Lowered Expectations for Astrana Health (NASDAQ:ASTH) Stock Price

Astrana Health (NASDAQ:ASTH - Get Free Report) had its target price cut by Truist Financial from $59.00 to $50.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Truist Financial's price target indicates a potential upside of 68.52% from the stock's current price.

Other research analysts have also issued research reports about the stock. TD Cowen started coverage on shares of Astrana Health in a research report on Monday, October 14th. They issued a "buy" rating and a $66.00 price target for the company. KeyCorp started coverage on Astrana Health in a report on Friday, October 11th. They issued a "sector weight" rating for the company. BTIG Research boosted their price target on Astrana Health from $60.00 to $70.00 and gave the company a "buy" rating in a research note on Thursday, October 3rd. Macquarie raised Astrana Health to a "hold" rating in a report on Monday, December 16th. Finally, Robert W. Baird boosted their target price on shares of Astrana Health from $67.00 to $86.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $63.67.

Astrana Health Stock Performance

Shares of NASDAQ:ASTH traded up $0.19 during trading on Monday, hitting $29.67. 77,574 shares of the stock were exchanged, compared to its average volume of 320,222. The company has a market capitalization of $1.67 billion, a price-to-earnings ratio of 22.82, a price-to-earnings-growth ratio of 1.80 and a beta of 1.20. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. Astrana Health has a 1-year low of $29.08 and a 1-year high of $63.20. The company's fifty day simple moving average is $39.55 and its 200-day simple moving average is $47.05.

Astrana Health (NASDAQ:ASTH - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, hitting analysts' consensus estimates of $0.33. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The firm had revenue of $478.71 million for the quarter, compared to the consensus estimate of $462.01 million. During the same quarter in the previous year, the company earned $0.47 earnings per share. Sell-side analysts expect that Astrana Health will post 1.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Astrana Health

A number of institutional investors have recently modified their holdings of ASTH. State Street Corp bought a new position in Astrana Health in the 3rd quarter worth approximately $91,966,000. Geode Capital Management LLC acquired a new stake in Astrana Health in the third quarter worth about $58,995,000. FMR LLC bought a new stake in Astrana Health during the 3rd quarter worth about $48,413,000. SteelPeak Wealth LLC acquired a new position in Astrana Health during the 3rd quarter valued at about $39,398,000. Finally, Loomis Sayles & Co. L P acquired a new stake in shares of Astrana Health during the 3rd quarter worth approximately $30,251,000. 52.77% of the stock is owned by institutional investors.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.